More Stories

Informist, Wednesday, Jun. 24, 2026

--Biocon arm to supply insulin to Malaysia-based Duopharma Biotech's arm 

--Biocon: To supply insulin for Duopharma's INR 5 bln order from Malaysia govt 

--Biocon spokesperson: Co sole supplier of insulin for Duopharma's order 

MUMBAI – Biocon Ltd.'s subsidiary will supply insulin to Malasiya-based Duopharma (M) Sendirian Berhad for the latter's contracts worth 225 million Malaysian ringgits (over INR 5 billion), Biocon said in an exchange filing Wednesday. Biocon's subsidiary will supply short-acting recombinant human insulin, insulin glargine, and insulin aspart to the Malasiyan company. 

While the filing didn't specify how much the Indian company stands to get from the contract, a company spokesperson said Biocon was the only supplier for Duopharma's insulin order. Duopharma has got the contract from Malaysia's Ministry of Health. The contract includes a three-year pact to supply human insulin worth 155.27 million Malaysian ringgits, and a two-year pact for insulin aspart and insulin glargine worth 70.5 million Malaysian ringgits.

Biocon has been suppling insulin to Duopharma since 2016 for diabetic patients in Malasiya. "Beyond diabetes care, both companies have also worked closely in oncology for more than seven years and have recently expanded into ophthalmology biologics, further improving access to high quality biologic therapies for patients across Malaysia," the company said in the release.

For the March quarter, Biocon reported a consolidated net profit of INR 1.26 billion on revenues of INR 45.17 billion. At 1123 IST, its shares were at INR 422.50 on the National Stock Exchange.  End

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

Reported by Anshul Choudhary

Edited by Avishek Dutta

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.